Pembrolizumab ( DrugBank: Pembrolizumab )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 25 | Progressive multifocal leukoencephalopathy | 1 |
| 285 | Fanconi anemia | 1 |
25. Progressive multifocal leukoencephalopathy
Clinical trials : 26 / Drugs : 35 - (DrugBank : 22) / Drug target genes : 8 - Drug target pathways : 37
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04091932 (ClinicalTrials.gov) | August 20, 2019 | 15/9/2019 | Treatment of PD-1 Inhibitor in AIDS-associated PML | The Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Progressive Multifocal Leukoencephalopathy (PML): A One-center, Single-arm and Prospective Study | Progressive Multifocal Leukoencephalopathy;AIDS | Drug: Pembrolizumab | First Affiliated Hospital of Zhejiang University | NULL | Recruiting | 18 Years | 65 Years | All | 10 | Phase 2 | China |
285. Fanconi anemia
Clinical trials : 62 / Drugs : 93 - (DrugBank : 30) / Drug target genes : 30 - Drug target pathways : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04483544 (ClinicalTrials.gov) | December 3, 2020 | 20/7/2020 | Pembrolizumab and Olaparib in Cervical Cancer Patients | Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway | Cervical Cancer;Cervical Carcinoma | Drug: pembrolizumab;Drug: olaparib | Baptist Health South Florida | Florida Department of Health;Merck Sharp & Dohme LLC | Recruiting | 18 Years | N/A | Female | 48 | Phase 2 | United States |